SNAPShot Learning: Update on GLP-1 receptor agonist availability

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have several clinical benefits for patients with type 2 diabetes, including robust glycaemic efficacy, weight loss, and cardiovascular benefits.1,2

From 1st August 2021, Bydureon® (exenatide XR) will no longer be available in Australia due to the discontinuation of global supply.

Guild Learning and Development has developed a short SNAPShot Learning course titled Update on GLP-1 receptor agonist availability for type 2 diabetes.

This course discusses what the discontinuation means for patients and how you can assist them to transition to other GLP-1 receptor agonists for their type 2 diabetes management. It also reviews the use and place in therapy of GLP-1RAs in the management of type 2 diabetes.

This course will take about 15 minutes to complete. It is not CPD accredited but pharmacists can self-record using the ‘self-record’ function.

To enrol in this course please visit guilded.guild.org.au

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.